Macro Group Pharmaceutical S.A.E

Macro Group Pharmaceutical S. A. E is a Cairo-based company focused on developing and manufacturing healthcare and personal care products to enhance beauty and well-being through a diverse range of solutions. Founded in 2002 in Cairo, Egypt, Macro Group Pharmaceuticals specializes in the production of healthcare and personal care products.

In February 2022, the company raised EGP 1. 283 billion through an IPO, marking a significant milestone in its growth. The company has completed 2 deals to date, with the most recent funding round being the IPO that valued the company at EGP 2. 8 billion.

Alta Semper Capital exited its investment following this significant transaction. Macro Group Pharmaceuticals specializes in a comprehensive range of healthcare and personal care products aimed at enhancing beauty and well-being. The company's core offerings include topical muscle relaxants, skin care products, hair care solutions, female intimate care items, oral care products, antiseptics, and anti-scar treatments. These products are designed to address various consumer needs, such as muscle discomfort relief, skin health improvement, and overall personal hygiene.

Macro's products are tailored for diverse end users, including individuals seeking effective skin and hair care solutions, healthcare professionals recommending topical therapies, and retailers distributing these products across multiple markets. The company actively markets its products in regions including the Middle East, North Africa, and select European and Asian markets, ensuring a wide reach among its target demographic. In 2021, Macro Group Pharmaceuticals reported a revenue of EGP 37,858,722. 20 and an EBITDA of EGP 13,392,605.

10. The company operates through a structured transaction model that emphasizes B2B relationships with wholesalers and retailers, as well as direct-to-consumer sales channels. Revenue is primarily generated from its diverse health and beauty product offerings, which are marketed within competitive pricing tiers and distributed through partnerships with pharmacies and healthcare providers. Following its IPO in February 2022, which raised EGP 1.

283 billion, Macro Group Pharmaceutical S. A. E plans to leverage this funding to expand its product offerings and geographical footprint. The company aims to introduce new product lines within the healthcare and personal care sectors in the upcoming year.

Additionally, Macro is targeting growth in new markets across the Middle East and North Africa, as well as specific regions in Europe and Asia, to further strengthen its market presence. The recent funding is expected to play a crucial role in supporting these initiatives.